English Español

Jason A. Efstathiou, MD, DPhil

Massachusetts General Hospital – Boston, MA

Dr. Efstathiou serves as the Director of the Genitourinary (GU) Division in Radiation Oncology and Clinical Co-Director of The Claire and John Bertucci Center for GU Cancers Multidisciplinary Clinic at the Massachusetts General Hospital (MGH). He holds a B.S. from Yale University, M.D. from Harvard Medical School (HMS), D.Phil. from the University of Oxford, and completed his residency training in the Harvard Radiation Oncology Program. Dr. Efstathiou’s clinical practice focuses on treatment of patients with bladder cancer and other urologic cancers. His commitment to service/patient care has been recognized as honoree for the MGH Cancer Center’s “The One Hundred” and as nominee for the Brian A. McGovern Award for Clinical Excellence. His research has informed clinical practice guidelines and has focused on long-term outcomes and late toxicities following trimodality bladder-sparing chemoradiation for muscle-invasive bladder cancer (results have helped inform NCCN and ICUD-EAU Bladder Cancerclinical guidelines offering bladder-preserving therapy as a safe and effective alternative to cystectomy in selected patients); as well as investigations into technology assessment and comparative effectiveness of emerging therapies for the treatment of genitourinary cancers.

He is the recipient of significant grant funding and serves as Principal Investigator of multiple studies including a NCI-sponsored multi-center randomized phase III trial of advanced radiation technologies in prostate cancer using patient-reported outcomes. Dr. Efstathiou lectures nationally and internationally and holds leadership positions in Radiation Oncology including serving as Chair of the GU Scientific Track for the American Society of Radiation Oncology (ASTRO). He is actively involved in clinical trial design both at his institution and within national cooperative groups, serving as NRG Oncology co-Chair of Comparative Effectiveness, Study co-Chair of NRG-GU001 (randomized phase II trial of postoperative adjuvant IMRT following cystectomy for pT3/4 urothelial bladder cancer), and member of the NRG GU and Advanced Technology Steering Committees. He also serves as co-Chair of the National Cancer Institute (NCI) Bladder Cancer Task Force.

Other projects of his include the development of web-based patient decision aids/support tools, evaluating the multidisciplinary approach to cancer care, and global oncology outreach efforts with Botswana-. His research publications along with other information can be viewed here.